A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC

NCT05839197 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Macrotrabecular Massive Hepatocellular Carcinoma

Interventions

PROCEDURE: HAIC
DRUG: Camrelizumab plus Apatinib

Sponsor

Wan-Guang Zhang